Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Stocks | 101.140 | 101.140 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 19.451 | 20.556 |
Price to Book | 3.289 | 4.182 |
Price to Sales | 2.288 | 2.480 |
Price to Cash Flow | 17.168 | 16.880 |
Dividend Yield | 1.171 | 1.341 |
5 Years Earnings Growth | 13.596 | 13.206 |
Number of long holdings: 59
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UnitedHealth | US91324P1021 | 6.72 | 520.69 | -0.73% | |
Medincell | FR0004065605 | 5.70 | 16.48 | -2.25% | |
Eli Lilly | US5324571083 | 3.98 | 799.90 | +1.61% | |
Boston Scientific | US1011371077 | 3.04 | 94.88 | -1.12% | |
Novartis | CH0012005267 | 2.96 | 91.09 | -0.60% | |
Becton Dickinson | US0758871091 | 2.84 | 233.67 | -0.32% | |
Merck&Co | US58933Y1055 | 2.78 | 99.25 | -0.60% | |
Thermo Fisher Scientific | US8835561023 | 2.40 | 542.31 | -0.48% | |
Fresenius SE | DE0005785604 | 2.20 | 35.080 | +0.03% | |
CSL | AU000000CSL8 | 2.19 | 285.09 | -0.86% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pluvalca Disruptive Opportunities A | 121.53M | -3.54 | -13.90 | - | ||
Pluvalca France Small Caps A | 92.75M | -4.72 | -5.99 | 5.06 | ||
Pluvalca Initiatives PME A | 73.57M | -8.42 | -10.72 | 7.32 | ||
Pluvalca Allcaps A | 55.36M | -1.91 | -1.24 | 6.05 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review